How Biotechs Can De-Risk CNS Clinical Development Through Early Modeling, Simulation and Study Design

A guide to accelerating CNS clinical development programs with data-driven insights, targeted populations, and regulator-ready evidence

This white paper explores how the early integration of modeling & simulation, as well as strategic study design, can help to de-risk CNS clinical development. CNS programs present a unique set of challenges due to limited biomarker availability, intricate patient demographics, high incidence of placebo responses in psychiatric indications, and difficulties with effective blood-brain barrier penetration. Consequently, CNS clinical development is often complicated, long, and costly, with significant uncertainty in trials demonstrating efficacy. Through the incorporation of model-informed drug development (MIDD) early in the clinical development process, sponsors can better predict the responses of the brain to drug exposure. This can help to optimize the process of dose selection and understand and anticipate drug-drug interactions before clinical trials.

Through several examples across different neurodegenerative, psychiatric, and rare pediatric indications, this white paper demonstrates the importance and benefits of pharmacokinetic/pharmacodynamic (PK/PD) modeling, physiologically based pharmacokinetic (PBPK) simulations, and exposure-response analyses. These are shown to be instrumental in guiding trial design, supporting regulatory submissions, and in some cases even reducing the need for additional clinical studies. The use of these quantitative approaches enables biopharma and collaborators to translate complex biological and clinical data into actionable insights that improve decision-making across the development pipeline.

The paper emphasizes the necessity of early regulator engagement, designing patient-centric studies, as well as planning for challenges in recruitment and retention through feasibility assessments. Finally, it highlights emerging trends in neuroscience research such as biomarker-driven stratification, digital health technology incorporation, and AI-enabled data analysis, which together will help transform the clinical development landscape for neuroscience therapies.